表紙
市場調査レポート

アジア太平洋地域のてんかん治療薬市場:効能・安全性を強化した次世代の抗てんかん薬(AED)による治療オプションの拡充

Epilepsy Therapeutics in Asia Pacific Markets to 2019 - Treatment Options Enhanced As Novel Next Generation AEDs Show Improved Safety and Tolerability

発行 GBI Research 商品コード 297629
出版日 ページ情報 英文
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=105.42円で換算しております。
Back to Top
アジア太平洋地域のてんかん治療薬市場:効能・安全性を強化した次世代の抗てんかん薬(AED)による治療オプションの拡充 Epilepsy Therapeutics in Asia Pacific Markets to 2019 - Treatment Options Enhanced As Novel Next Generation AEDs Show Improved Safety and Tolerability
出版日: 2014年03月14日 ページ情報: 英文
概要

アジア太平洋地域における癲癇治療薬の市場規模は、2012年現在で11億米ドルに達し、さらに2019年までに年平均(CAGR)4.7%の速度で成長して、2019年には15億米ドルにまで拡大する、と推計されています。市場成長の主な要因として、中国・インドでの発症率の高さや、中国での市場アクセス改善による治療薬普及率の上昇、新たな機能メカニズムを有する治療薬の上市見通しなどが挙げられます。一方で、特許失効によりジェネリック医薬品となった古い治療薬に対する需要もあり、それが今後の市場成長の制約となる可能性があります。

当レポートでは、アジア太平洋地域諸国におけるてんかん治療法の関連市場について分析し、疾患の概要や主な治療パターン、上市済み製品の概要(安全性・効能など)、現在開発中の治療薬のパイプライン情報、地域全体および主要国におけるの市場動向の見通し(今後8年間の予測値)、資本取引・事業提携の動きなどを調査して、その結果を概略以下の構成でお届けします。

第1章 目次

第2章 イントロダクション

  • 疾患の概要
  • 疫学
  • 症状
  • 病因
  • 病態整理
  • 共存症/併発症
  • 診断
  • 予後
  • 治療効率
  • 治療オプション
    • イオンチャネルモジュレーター
    • GABA作動性の促進
    • 興奮性アミノ酸阻害剤
    • シナプス系モジュレーター
  • 非薬物療法
    • 肺葉切除(ロベクトミー)および病巣切除(レシオネクトミー)
    • ケトン食療法および修正アトキンス食事療法
    • 迷走神経刺激

第3章 てんかんの治療環境

  • 概況
  • Lyrica (pregabalin)
  • Lamictal (lamotrigine)
  • Keppra (levetiracetam)
  • Zonegran (zonisamide)
  • Vimpat (lacosamide)
  • Aptiom/Zebinix (eslicarbazepine acetate)
  • Fycompa (perampanel)
  • Trobalt/Potiga (ezogabine/retigabine)
  • Banzel/Inovelon (rufinamide)
  • 上市製品の効能・安全性の比較

第4章 てんかん治療薬のパイプライン

  • パイプラインの全体的状況
  • 機能メカニズム別のパイプライン
  • 治験
    • 失敗率
    • 参加している患者数と治験の規模
    • 治験の期間
  • 有望なパイプライン候補
    • Brivaracetam(UCBが開発)
    • Ganaxolone(Marinus Pharmaceuticalsが開発)

第5章 てんかんの治療薬市場の将来予測(今後6年間分)

  • 各地域の市場動向
    • アジア太平洋地域の主要国
    • 中国
    • インド
    • 日本
    • オーストラリア
  • 市場促進・抑制要因
    • 市場促進要因
    • 市場抑制要因

第6章 資本取引と戦略的な企業統合

  • 資本取引の分析
  • 研究開発(R&D):共同開発契約
  • 研究開発(R&D):ライセンス契約

第7章 付録

図表一覧

目次
Product Code: GBIHC324MR

GBI Research, the leading business intelligence provider, has released its latest research, "Epilepsy Therapeutics in Asia Pacific Markets to 2019 - Treatment Options Enhanced As Novel Next Generation AEDs Show Improved Safety and Tolerability", which provides in-depth analysis of epilepsy market within the Asia-Pacific (APAC) market covering the four countries of Australia, China, India and Japan. The report provides an estimation of market size for 2012, along with market forecast until 2019. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis.

The value of the epilepsy market in the APAC region amounted to an estimated $1.1 billion in 2012 and is expected to register a Compound Annual Growth Rate (CAGR) of 4.7% to reach $1.5 billion by 2019. The key drivers for growth in the APAC market include: high prevalence in China and India, increased market penetration due to improved market access in China and the expected approvals of drugs with novel mechanisms of action which could expand the therapeutic scope. Conversely, the growth of the market in APAC region could face the restricting influence of prescribing patterns that give preference to older generation drugs and also due to generic competition as a result of key patent expiries.

Scope

The report analyzes treatment usage patterns, market characterization, pipeline analysis and key licensing and co-development deals in anti-epileptics in the four APAC markets of Australia, China, India and Japan. The report includes -

  • A brief introduction to epilepsy, including disease pathogenesis, risk factors, diagnosis and treatment options
  • In-depth analysis of major marketed products covering product performance, product life-cycle and a heat map depicting comparative analysis of safety and efficacy parameters
  • A comprehensive review of the epilepsy pipeline which includes individual analysis of promising late-stage pipeline drugs that are likely to enter the market during the forecast period. The pipeline is analyzed on the basis of Phase distribution, molecule type and molecular target.
  • Additional clinical trial analysis by Phase, trial size, trial duration and program failure rate for each molecule type and mechanism of action
  • Multi-scenario forecasts of the epilepsy market from 2012 to 2019 in the four APAC regions
  • In-depth analysis of licensing and co-development agreements and an overview of key agreements that could impact growth trends
  • Key drivers and restraints that have had and are expected to have a significant impact upon the market

Reasons to buy

  • The report will enhance your decision-making capability by allowing you to -
  • Align your product portfolio to markets with high growth potential
  • Develop market entry and expansion strategies by identifying the potential regions and therapeutic segments poised for strong growth
  • Devise effective, tailored strategies for each country through the understanding of key drivers and barriers in the anti-epileptic drugs market
  • Develop key strategic initiatives based upon an understanding of key focus areas and leading companies
  • Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships

Abstract

Asia-Pacific Epilepsy Therapeutics Market Continues to Grow as New Drugs Emerge, says GBI Research

The epilepsy therapeutics market value in the Asia-Pacific (APAC) region - Australia, China, India and Japan - is expected to increase moderately, climbing from $1.1 billion in 2012 to $1.5 billion by 2019, at a Compound Annual Growth Rate (CAGR) of 4.7%, forecasts business intelligence provider GBI Research.

According to the firm's latest report*, China and India are expected to show the fastest growth over the forecast period, with CAGRs of 6.1% and 4.2%, respectively. Meanwhile, Australia and Japan will witness slightly lower CAGRs of 3.9% and 1.7%.

Vijaya Vulapalli, Senior Analyst for GBI Research, says: "With a high epilepsy prevalence, China and India have large treatment populations, which are expected to increase further in the future due to better healthcare access and an improvement in treatment gaps."

GBI Research states that the epilepsy sector is still dominated by older generation Anti-Epileptic Drugs (AEDs), such as carbamazepine, valproate, oxcarbazepine and phenytoin, which account for a combined share of over 60% of the APAC region's market. Historically, these AEDs have had poor safety and tolerability profiles.

However, second generation AEDs with newer mechanisms of action, such as Keppra (levetiracetam), Zonegran (zonisamide) and Vimpat (lacosamide), have signaled a shift in the last decade with improved tolerability and efficacy. Recent approvals, including Fycompa (perampanel) and Trobalt (retigabine) have continued this trend by focusing on new molecular targets.

Vulapalli concludes: "Approximately 20 to 30% of epilepsy patients fail to respond to treatment with existing AEDs. This population forms a sizeable chunk of the market, which is promising for new entrants. Both Fycompa and Trobalt have the potential to address refractory epilepsy patient needs when launched in their respective markets."

Epilepsy Therapeutics in Asia Pacific Markets to 2019 - Treatment Options Enhanced As Novel Next Generation AEDs Show Improved Safety and Tolerability

This report provides analysis of the epilepsy market within the Asia-Pacific region covering Australia, China, India and Japan. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis.

This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GBI Research's team of industry experts.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Disease Overview
  • 2.2. Epidemiology
  • 2.3. Symptoms
  • 2.4. Etiology
  • 2.5. Pathophysiology
  • 2.6. Co-morbidities/Complications
  • 2.7. Diagnosis
  • 2.8. Prognosis
  • 2.9. Treatment Efficacy
  • 2.10. Treatment Options
    • 2.10.1. Ion Channel Modulators
    • 2.10.2. GABA-ergic Facilitation
    • 2.10.3. Excitatory Amino Acid Inhibitors
    • 2.10.4. Synaptic Modulators
  • 2.11. Non-pharmacological Management
    • 2.11.1. Lobectomy and Lesionectomy
    • 2.11.2. Ketogenic Diet and Modified Atkins Diet
    • 2.11.3. Vagus Nerve Stimulation

3. Epilepsy Therapeutic Landscape

  • 3.1. Overview
  • 3.2. Lyrica (pregabalin)
  • 3.3. Lamictal (lamotrigine)
  • 3.4. Keppra (levetiracetam)
  • 3.5. Zonegran (zonisamide)
  • 3.6. Vimpat (lacosamide)
  • 3.7. Aptiom/Zebinix (eslicarbazepine acetate)
  • 3.8. Fycompa (perampanel)
  • 3.9. Trobalt/Potiga (ezogabine/retigabine)
  • 3.10. Banzel/Inovelon (rufinamide)
  • 3.11. Comparative Efficacy and Safety of Marketed Products

4. Pipeline for Epilepsy Therapeutics

  • 4.1. Overall Pipeline
  • 4.2. Pipeline by Mechanism of Action
  • 4.3. Clinical Trials
    • 4.3.1. Failure Rate
    • 4.3.2. Patient Enrolment and Clinical Trial Size
    • 4.3.3. Clinical Trial Duration
  • 4.4. Promising Pipeline Candidates
    • 4.4.1. Brivaracetam - UCB
    • 4.4.2. Ganaxolone - Marinus Pharmaceuticals

5. Epilepsy Therapeutics Market Forecast to 2019

  • 5.1. Geographical Markets
    • 5.1.1. Key Asia-Pacific Markets
    • 5.1.2. China
    • 5.1.3. India
    • 5.1.4. Japan
    • 5.1.5. Australia
  • 5.2. Drivers and Barriers
    • 5.2.1. Drivers
    • 5.2.2. Barriers

6. Deals and Strategic Consolidations

  • 6.1. Deals Analysis
  • 6.2. Research and Development Co-development Agreements
  • 6.3. Research and Development Licensing Agreements

7. Appendix

  • 7.1. Abbreviations
  • 7.2. References
  • 7.3. References for Heat Maps
  • 7.4. Pipeline Products by Phase
    • 7.4.1. Discovery
    • 7.4.2. Preclinical
    • 7.4.3. IND-filed and Phase 0
    • 7.4.4. Phase I
    • 7.4.5. Phase II
    • 7.4.6. Phase III
    • 7.4.7. Pre-registration
  • 7.5. Market Forecasting Data Tables to 2019
    • 7.5.1. Asia-Pacific
    • 7.5.2. China
    • 7.5.3. India
    • 7.5.4. Japan
    • 7.5.5. Australia
  • 7.6. Research Methodology
    • 7.6.1. Coverage
    • 7.6.2. Secondary Research
    • 7.6.3. Primary Research
    • 7.6.4. Therapeutic Landscape
    • 7.6.5. Geographical Landscape
    • 7.6.6. Pipeline Analysis
  • 7.7. Expert Panel Validation
  • 7.8. Contact Us
  • 7.9. Disclaimer

List of Tables

  • Table 1: Epilepsy Therapeutics, Global, Types of Seizures, 2013
  • Table 2: Epilepsy Therapeutics, Heat Maps for Efficacy and Safety of Marketed Products, References
  • Table 3: Epilepsy Therapeutics, Global, Pharmaceutical Pipeline (Discovery), 2013
  • Table 4: Epilepsy Therapeutics, Global, Pharmaceutical Pipeline (Preclinical), 2013
  • Table 5: Epilepsy Therapeutics, Global, Pharmaceutical Pipeline (IND/CTA-filed), 2013
  • Table 6: Epilepsy Therapeutics, Global, Pharmaceutical Pipeline (Phase I), 2013
  • Table 7: Epilepsy Therapeutics, Global, Pharmaceutical Pipeline (Phase II), 2013
  • Table 8: Epilepsy Therapeutics, Global, Pharmaceutical Pipeline (Phase III), 2013
  • Table 9: Epilepsy Therapeutics, Global, Pharmaceutical Pipeline (Pre-registration), 2013
  • Table 10: Epilepsy Therapeutics, Asia-Pacific, Market Forecast, 2012-2019
  • Table 11: Epilepsy Therapeutics, China, Market Forecast, 2012-2019
  • Table 12: Epilepsy Therapeutics, India, Market Forecast, 2012-2019
  • Table 13: Epilepsy Therapeutics, Japan, Market Forecast, 2012-2019
  • Table 14: Epilepsy Therapeutics, Australia, Market Forecast, 2012-2019

List of Figures

  • Figure 1: Epilepsy Therapeutics, Epidemiology, Asia-Pacific, 2012
  • Figure 2: Epilepsy Therapeutics, Lyrica, Global, Revenue ($bn), 2013
  • Figure 3: Epilepsy Therapeutics, Lamictal, Global, Revenue ($m), 2009-2013
  • Figure 4: Epilepsy Therapeutics, Keppra, Global, Revenue ($bn), 2009-2013
  • Figure 5: Epilepsy Therapeutics, Zonegran, Global, Revenue ($m), 2009-2013
  • Figure 6: Epilepsy Therapeutics, Vimpat, Global, Revenue ($m), 2009-2013
  • Figure 7: Epilepsy Therapeutics, Global, Comparative Safety and Efficacy of Marketed Products (Heat Map), 2013
  • Figure 8: Epilepsy Therapeutics, Global, Overall Pipeline Analysis, 2013
  • Figure 9: Epilepsy Therapeutics, Global, Pipeline Analysis, by Mechanism of Action, 2013
  • Figure 10: Epilepsy Therapeutics, Global, Clinical Trial Failure Rate, 2013
  • Figure 11: Epilepsy Therapeutics, Global, Pipeline, Clinical Trial Size, 2013
  • Figure 12: Epilepsy Therapeutics, Global, Pipeline, Clinical Trial Duration, 2013
  • Figure 13: Epilepsy Therapeutics, Asia-Pacific, Market Size, 2012-2019
  • Figure 14: Epilepsy Therapeutics, China, Market Size, 2012-2019
  • Figure 15: Epilepsy Therapeutics, India, Market Size, 2012-2019
  • Figure 16: Epilepsy Therapeutics, Japan, Market Size, 2012-2019
  • Figure 17: Epilepsy Therapeutics, Australia, Market Size, 2012-2019
  • Figure 18: Epilepsy Therapeutics, Deals by Region, Value and Year, 2006-2013
  • Figure 19: Epilepsy Therapeutics, Deals by Molecule Type and Mechanism of Action, 2006-2013
  • Figure 20: Epilepsy Therapeutics, Co-development Deals, Territory, 2006-2013
  • Figure 21: Epilepsy Therapeutics, Licensing Deals, by Territory, 2006-2013
  • Figure 22: GBI Research Market Forecasting Model
Back to Top